Monopar Therapeutics
MNPRNasdaq
$111.12
↑ +2.4%Jul 17 close · end-of-day
Price
1Y↑ +170.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$15.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-11.1%
ROIC
-48.5%
Debt / Equity
—
Net Cash
$104.9M
Return 1Y
+135.2%
Company profile
Monopar Therapeutics Inc. engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
- CEO
- Chandler D. Robinson
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- Illinois
- Website
- monopartx.com
Management & directors
- Cittadine AndrewChief Operating Officer
- Robinson ChandlerChief Executive Officer
- Vu Quan AnhChief Financial Officer
- Tactic Pharma LlcChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
MNPR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.5M | -$9.1M | -$10.5M | -$8.8M | -$16.2M | -$16.7M |
| Net income | -$6.3M | -$9.1M | -$10.5M | -$8.4M | -$15.6M | -$13.7M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$4.7M | -$7.3M | -$7.2M | -$7.9M | -$6.4M | -$12.2M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.8M | -$1.6M | -$11.1M | -$3.2M | -$3.2M | -$4.1M | -$6.2M | -$5.2M |
| Net income | -$1.7M | -$1.3M | -$10.9M | -$2.6M | -$2.5M | -$3.4M | -$5.2M | -$3.9M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$1.7M | -$1.1M | -$2.0M | -$5.7M | -$1.1M | -$2.1M | -$3.4M | -$3.5M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Robinson Chandler· Chief Executive Officer | Tax withholding | 4,084 | $92.59 | $378,137.56 | filing |
| 2026-06-30 | Cittadine Andrew· Chief Operating Officer | Tax withholding | 2,309 | $92.59 | $213,790.31 | filing |
| 2026-06-30 | Vu Quan Anh· Chief Financial Officer | Tax withholding | 507 | $92.59 | $46,943.13 | filing |
| 2026-06-30 | Vu Quan Anh· Chief Financial Officer | Option exercise | 1,228 | — | — | filing |
| 2026-06-30 | Robinson Chandler· Chief Executive Officer | Option exercise | 12,873 | — | — | filing |
| 2026-06-30 | Cittadine Andrew· Chief Operating Officer | Option exercise | 5,254 | — | — | filing |
| 2026-03-31 | Robinson Chandler· Chief Executive Officer | Tax withholding | 1,972 | $54.79 | $108,045.88 | filing |
| 2026-03-31 | Cittadine Andrew· Chief Operating Officer | Tax withholding | 1,571 | $54.79 | $86,075.09 | filing |
| 2026-03-31 | Robinson Chandler· Chief Executive Officer | Option exercise | 6,732 | — | — | filing |
| 2026-03-31 | Cittadine Andrew· Chief Operating Officer | Option exercise | 3,514 | — | — | filing |
| 2025-12-31 | Robinson Chandler· Chief Executive Officer | Tax withholding | 2,558 | $65.30 | $167,037.40 | filing |
| 2025-12-31 | Cittadine Andrew· Chief Operating Officer | Tax withholding | 1,889 | $65.30 | $123,351.70 | filing |
| 2025-12-31 | Robinson Chandler· Chief Executive Officer | Option exercise | 8,724 | — | — | filing |
| 2025-12-31 | Cittadine Andrew· Chief Operating Officer | Option exercise | 4,326 | — | — | filing |
| 2025-12-26 | Vu Quan Anh· Chief Financial Officer | Buy | 1,500 | $69.95 | $104,925.00 | filing |
| 2025-12-18 | KLAUSNER ARTHUR J | Sale | 4,660 | $67.06 | $312,499.60 | filing |
| 2025-12-18 | KLAUSNER ARTHUR J | Sale | 461 | $68.09 | $31,389.49 | filing |
| 2025-12-16 | Hendricks Diane | J | 43,499 | $0.00 | $0.00 | filing |
| 2025-12-16 | KLAUSNER ARTHUR J | J | 7,710 | $0.00 | $0.00 | filing |
| 2025-09-30 | Robinson Chandler· Chief Executive Officer | Tax withholding | 2,646 | $81.67 | $216,098.82 | filing |
| 2025-09-30 | Cittadine Andrew· Chief Operating Officer | Tax withholding | 1,896 | $81.67 | $154,846.32 | filing |
| 2025-09-30 | Cittadine Andrew· Chief Operating Officer | Option exercise | 4,327 | — | — | filing |
| 2025-09-30 | Robinson Chandler· Chief Executive Officer | Option exercise | 8,726 | — | — | filing |
| 2025-09-24 | Tactic Pharma LLC· Chief Executive Officer | Sale | 550,229 | $63.61 | $35.0M | filing |
| 2025-07-14 | STARR CHRISTOPHER M | Sale | 16,800 | $40.00 | $672,020.16 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.